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Introduction: Following the consensus deﬁnition of cancer cachexia, more studies are using CT scan
analysis of truncal muscles as a marker of muscle wasting. However, how CT-derived body composition
relates to function, strength and power in patients with cancer is largely unknown.
Aims: We aimed to describe the relationship between CT truncal (L3) skeletal muscle index (SMI) and
MRI quadriceps cross sectional area with lower limb strength, power and measures of complex function.
Methods: Patients undergoing assessment for potentially curative surgery for oesophagogastric or
pancreatic cancer were recruited from the regional upper gastrointestinal (UGI) or hep-
atopancreaticobiliary (HPB) multi-disciplinary team meetings. Maximum Isometric Knee Extensor
Strength (IKES) and Maximum Leg Extensor Power (Nottingham Power Rig) (LEP) were used as measures
of lower limb performance. Both Sit to Stand (STS) and Timed Up and Go (TUG) were used as measures of
global complex muscle function. Muscle SMI was measured from routine CT scans at the level of the third
lumbar vertebrae (L3) and MRI scan was used for the assessment of quadriceps muscles. Linear
regression analysis was performed for CT SMI or MRI quadriceps as a predictor of each measure of
performance.
Results: Forty-four patients underwent assessment. Height and weight were signiﬁcantly related to
function in terms of quadriceps power, while only weight was associated with strength (P < 0.001). CT
SMI was not related to measures of quadriceps strength or power but had signiﬁcant association with
more complex functional measures (P ¼ 0.006, R2 ¼ 0.234 and 0.0019, R2 ¼ 0.175 for STS and TUG
respectively). In comparison, both gross and fat-subtracted measures of quadriceps muscle mass from
MRI were signiﬁcantly correlated with quadriceps strength and power (P < 0.001), but did not show any
signiﬁcant association with complex functional measures.
Conclusion: CT SMI and MRI quadriceps have been shown to reﬂect different aspects of functional ability
with CT SMI being a marker of global muscle function and MRI quadriceps being speciﬁc to quadriceps
power and strength. This should therefore be considered when choosing outcome measures for trials or
deﬁnitions of muscle mass and function.
© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).ces, University of Edinburgh,
cent, Edinburgh, EH16 4SA,
r Ltd. This is an open access article1. Introduction
Muscle mass may be measured during muscle wasting as a
marker of disease severity, progression or response to treatment. As
currently there are no quantitative surrogate biochemical markers
for muscle wasting, evaluation relies on direct assessment of
muscle mass. Typically, these assessments measure limb muscleunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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indexed for height - skeletal muscle index (SMI)]. These muscle
groups may have different biological responses to cancer cachexia,
and thus may make different relative contributions to reduced
physical function, perhaps the most important clinical sequela of
muscle wasting in cancer cachexia or aging.
Studies of muscle size and function typically assess strength or
power along with CT SMI and volume in speciﬁc muscle groups.
This relationship is well studied in healthy individuals [1,2] and in
aging [3], with a clear correlation seen between muscle mass and
strength [4,5]. Despite such correlations, there is signiﬁcant varia-
tion in muscle strength and power between individuals, not
explained by simple differences in sex or lean mass [5]. This vari-
ation has been extensively studied in aging where age-related
changes in muscle quality may contribute to changes in muscle
function in terms of strength and power [6]. Although SMI is
commonly reported in the assessment of cancer cachexia, the
relationship of muscle area or volumewith strength or power is not
well described in this patient group. This question is of particular
importance as pain, fatigue and symptoms associated with cancer
or cancer treatment, as well as alterations in intramuscular fat, will
all affect the functional performance of these patients [7]. There-
fore, in studies of cancer patients, it is not always practical or
appropriate to undertake extensive investigation that adds to the
burden of routine cancer investigation or treatment, particularly
with regard tomeasures requiring signiﬁcant physical exertion. Use
of routine diagnostic CT scans is cheaper, quicker, reduces patient
burden and also allows for retrospective analysis [8]. This modality
is now extensively used but has not been validated against function,
limb strength and power in patients with cancer.
The commonly studied muscle groups include the muscles of
the lower limb, thigh and quadriceps, or the upper limb biceps area
or forearm muscles involved in hand grip strength [9,10]. These
muscles or muscle groups are chosen as they are known to be
functionally important in common actions such as chair rising and
stair climbing, or may contribute to clinically signiﬁcant events e.g.
falls in the elderly [11]. Additionally, complex functional measures
such as TUG and STS times are related to both muscle function and
to disability and risk of falls [12]. These measures of function may
be considered in a spectrum of complexity whereby “simple”
measures aim to assess a single muscle or muscle group such as
isometric knee extensor strength (IKES). Dynamicmeasures such as
Leg extensor power (LEP), where the limb moves during the mea-
sure are more prone to recruit additional muscle groups and may
provide a less “pure” measure of an individual muscle group. In
comparison, the Sit to Stand (STS) test is a more complex functional
measure of muscle strength and power that also involves coordi-
nation of lower limb and truncal muscles, whereas the Timed Up
and Go (TUG) is more “complex” still involving both muscle
strength, power, coordination and balance.
Therefore, we aimed to describe the relationship between CT
truncal (L3) skeletal muscle index (SMI) and MRI quadriceps cross
sectional area with lower limb strength, power and measures of
complex function.
2. Methods
2.1. Patient recruitment
Patients were recruited from the regional upper gastrointestinal
(UGI) or hepatopancreaticobiliary (HPB) multi-disciplinary meet-
ings prior to undergoing potentially curative surgery for oesopha-
gogastric or pancreatic cancer. Ethical approval was granted by the
Lothian research ethics committee. Written informed consent was
obtained. Cachexia was deﬁned according to the consensusdeﬁnition [13]. All patients who took part in the study were
deemed ﬁt enough to undergo major resectional surgery. Patients
were excluded if they had signiﬁcant musculoskeletal problems
limiting their ability to perform the tests. Isometric tests of truncal
muscle strength were not performed. Biodex systems do exist to
measure isometric truncal muscle function but have not been
validated in this patient group.
2.2. Maximum Isometric Knee Extensor Strength (strain gauge)
(IKES)
IKES was measured with a strain gauge and recorded with a
strain meter. Three separate measurements (Newtons) were ob-
tained for each limb and the highest value from the dominant limb
used in subsequent analysis. The coefﬁcient of variation for IKES is
6.9% for a single session and 10% across sessions occurring over
several days [14].
2.3. Maximum Leg Extensor Power (Nottingham Power Rig) (LEP)
LEP was measured using the Nottingham Power Rig. The in-
strument consists of an adjustable seat and large foot pedal con-
nected to a ﬂywheel. The ﬁnal velocity of the ﬂywheel was used to
calculate the average power output (Watts) during a single
maximal thrust of the lower limb. The process was repeated ﬁve
times with each limb and the highest value from the dominant limb
used in subsequent analysis. The coefﬁcient of variation for
repeated tests of leg extensor power measured using the Notting-
ham power rig in healthy individuals is 8.7% [14].
2.4. Measures of complex function
TUG was measured in conjunction with the STS test by two
observers as per previous publications [15e17].
2.5. Imaging analysis
CT imaging was chosen for this study as it is now considered the
gold standard for body composition analysis. It is easily accessible
in this patient group as it is routinely performed as part of the
assessment process for cancer patients. CT scans however do not
encompass imaging of the whole body and therefore MRI quadri-
ceps was undertaken. Although not widely used in cachexia clinical
trials before MRI quadriceps has been used successfully in the
Formoterol trial [18].
SMI was measured from routine CT scans performed within 42
days of functional measurement and prior to any surgical inter-
vention or neoadjuvant chemotherapy. Digitally stored CT images
completed with a spiral CT were analysed as described previously
[19,20]. Cross-sectional area for muscle was normalized for stature
(cm2/m2) and a lumbar SMI computed. SMI cut-offs for low SMI
were based on a CT-based study of cancer patients by Martin et al.
[10]. Cachexia was classiﬁed according to the consensus deﬁnition
by Fearon et al. (>5% weight loss or >2% weight loss and low
muscularity) [13]. Skeletal muscle density (SMD) was assessed by
the mean radiological muscle attenuation of all muscle visible at
the L3 level, measured in Hounsﬁeld Units (HU). The HU scale is a
radiological scale describing the density of tissues on CT scans;
lower mean muscle attenuation indicates less dense muscle tissue
withmore lipid inﬁltration [21]. There is currently no consensus for
the upper and lower HU cut-offs used to characterize muscle
attenuation. In previous studies we have used mean HU for skeletal
muscle values below 39.5 (two standard deviations below a normal
healthy cohort) to classify low muscle attenuation [22].
Table 1
Group characteristics for patients with upper GI cancer undergoing cross sectional
imaging and functional assessment.
Descriptive Statistics
Range Mean Std. Deviation
Age (years) 39e88 63.34 11.03
Height (M2) 1.52e1.90 1.70 0.09
Weight (kg) 48.80e121.70 74.26 15.94
Self-reported
weight change (%)
43.8e10.9 6.7 9.3
CRP (mg/L) 1e172 20 40
IKES (N) 91.5e548.0 262.9 95.0
LEP (W) 39.0e270.0 101.5 49.0
STS (s) 0.30e0.98 0.63 0.17
TUG (s) 4.21e12.53 7.02 1.64
MRI Quads CSA (cm2/m2) 12.59e25.62 18.35 3.37
MRI Quads k-means
CSA (cm2/m2)
9.00e23.97 15.38 3.44
CT SMI (cm2/m2) 34.38e58.40 44.51 6.10
Muscle mean HU 20e55 39.42 8.39
Table 3
Association of SMI of L3 muscle with quadriceps (Isometric Knee Extensor Strength
and Leg Extensor Power) and complex (Sit to stand, Timed Up and Go) function.
Quadriceps muscle
strength and power
Truncal (L3) SMI Truncal (L3) Muscle
HU
R2 P R2 P
Dominant IKES 0.068 0.150 0.032 0.325
Dominant LEP 0.081 0.103 0.014 0.509
Complex function (N ¼ 31)
STS 0.234 0.006 0.006 0.672
TUG 0.175 0.019 0.103 0.078
Signiﬁcant at p ¼ 0.025.
Bold represents statistically signiﬁcant.
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cross-sectional area (CSA) of muscle in each image was quantiﬁed
off-line using ANALYZE 8.0 (Mayo Clinic, Rochester, USA) by a
manual delineation technique. An automated in house programme
based on k-means clustering was applied to the manually
segmented image [23]. The purpose of this was to exclude areas of
fat lyingwithin themuscle or betweenmuscle groups to provide an
objective measure of healthy muscle tissue.
2.6. Statistical analysis
Linear regression analysis was performed for CT SMI or MRI
quadriceps CSA as a predictor for each measure of function.
Strength, power, STS and TUG were correlated with variables
known to be associated with function: SMI, SMD, CRP, weight,
height and weight loss. Statistical signiﬁcance was set at a two-
tailed p value of 0.05. Associations are described with r2 values
and uncorrected p values for each comparison. P values required for
signiﬁcance after Bonferroni correction for multiple comparisons
are displayed for each analysis. KolmogoroveSmirnov test was used
to assess for normality of distribution of data. As this was an
exploratory study a sample size calculation was not performed.
3. Results
Forty-four (16 female) patients underwent functional assess-
ment. Due to patient frailty and availability IKES was unavailable in
three patients, MRI quads in 14, CT in 10, STS and TUG in 4. Char-
acteristics of the overall group are described in Table 1. Nineteen
patients had low muscularity on CT scan and 28 were cachectic
according to the consensus deﬁnition.
On simple linear regression (p ¼ 0.001 was considered signiﬁ-
cant to account for multiple comparisons after BonferroniTable 2
Regression analysis of patient characteristics with functional measures.
Height (m) Weight (Kg) A
R2 P R2 P R
IKES (n ¼ 41) 0.049 0.166 0.287 <0.001 0
LEP (n ¼ 44) 0.225 0.001 0.199 0.002 0
STS (n ¼ 40) 0.003 0.748 0.000 0.983 0
TUG (n ¼ 40) 0.003 0.740 0.000 0.941 0
Signiﬁcant at p ¼ 0.001 (IKES ¼ Isometric Knee Extensor Strength, LEP ¼ Leg Extensor P
Bold represents statistically signiﬁcant.correction), height and weight were signiﬁcantly related to func-
tion in terms of quadriceps power, whilst only weight was associ-
ated with quadriceps strength. These associations could be
expected and provide the rationale behind correction of strength
and power for stature where they are used independently of other
body composition measures [24]. Age, CRP andweight-loss showed
weak associations with complex measures of function, but with the
exception of TUG with age, these associations lost signiﬁcance after
correction for multiple comparisons (Table 2).
CT SMI was not related to measures of quadriceps strength and
power (IKES, LEP) (Table 3), but was signiﬁcantly associated with
more complex functional measures (Table 3) (signiﬁcance at
p  0.025 for multiple comparisons). No relationship was seen
between any measure of muscle performance and CT-derived SMD
(Table 3).
Both MRI gross and fat-subtracted measures of quadriceps
musclemass were signiﬁcantly correlatedwith quadriceps strength
and power (Table 4). No association was seen with the more
complex functional measures (Table 4) (signiﬁcance at p ¼ 0.025)
Signiﬁcant correlations are shown in Figs. 1e4.4. Discussion
Measures of muscle mass from CT SMI and MRI quadriceps
both appear to relate to performance though measures from the
two different anatomical locations reﬂect different functional
abilities in this group of patients with cancer. This may be of
great importance in the design of future clinical trials. Previous
trials have failed as they have been able to demonstrate increases
in lean mass but not in functional outcomes [25]. This failure
may have been because speciﬁc functional read outs such as
hand grip strength were used rather than a more in depth
assessment of muscle function using various short physical per-
formance tests.
As might be expected, MRI-estimated quadriceps size corrected
for stature correlates with quadriceps strength and power. This
observation appears to be true whether the gross or fat-subtracted
area is used. This ﬁnding is consistent with previous studies inge (years) CRP (mg/l) Weight change
2 P R2 P R2 P
.001 0.861 0.113 0.032 0.116 0.029
.091 0.049 0.051 0.140 0.061 0.106
.101 0.045 0.050 0.163 0.087 0.065
.268 0.001 0.162 0.010 0.000 0.891
ower, STS ¼ Sit To Stand time, TUG ¼ Timed Up and Go).
Table 4
Association of height adjusted MRI measures of quadriceps muscle cross sectional
area with quadriceps function (Isometric Knee Extensor Strength, Leg Extensor
Power).
Quadriceps muscle
strength and power N ¼ 28
Quads Muscle CSA
(cm/m2) N ¼ 30
Quads K-means
muscle (cm/m2)
N ¼ 25
R2 P R2 P
Dominant IKES 0.399 <0.001 0.412 0.001
Dominant LEP 0.242 0.006 0.346 0.002
Complex function
STS 0.024 0.436 0.069 0.227
TUG 0.026 0.409 0.160 0.058
Signiﬁcant at p ¼ 0.025.
Bold represents statistically signiﬁcant.
Fig. 2. Scatter chart to show correlation between CT SMI and TUG.
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extensor strength in healthy young men (r ¼ 0.59) and women
(r ¼ 0.51) [5]. The data presented here suggest that fat subtracted
CSA could possibly be a more relevant measure as it appears that
similar or greater variance (r2) is described by the fat subtraction
method despite smaller numbers in this group (25 vs 30 in the gross
CSA group) and would be consistent with the principle that fat
inﬁltration of muscle is an important inﬂuence on muscle function
[26].However, thisﬁndingwasnot reproducedwhenusingHU/SMD
as ameasure of muscle fat inﬁltration on CT. CT-derived SMD differs
from MRI fat-subtracted muscle area in that although macroscopic
adipose tissue is excludedduring analysis of CTscans,microscopic or
intramyocellular deposits still remain [27]. SMDhas previously been
shown to correlate with muscle function in terms of mobility limi-
tation in healthy older people [28], but this ﬁnding was not repro-
duced in the present study in terms of strength, power or complex
tests of global muscle function. Other factors such as peripheral
oedema and gross alteration in hydration status may be present in
patients with cancer that can also inﬂuence skeletal muscle HU and
diminish the strength of this association [29]. With PET-CT now
becoming more widely available and used as part of routine cancer
staging future studies will be able to compare different muscle
groups using the same imaging technique.
MRI quadriceps did not correlate with outcome in complex tests
(i.e. STS and TUG). At ﬁrst glance, this ﬁnding may seem surprising
as quadriceps strength is normally the strongest predictor of STS
times in healthy individuals [28]. However, in community dwelling
older people, knee extensor strength explains only 16.5% of the
variance in the STS test [30] with other factors such as visual
contrast sensitivity, lower limb proprioception, peripheral tactile
sensitivity, reaction time, and scores on the Short-Form 12 HealthFig. 1. Scatter chart to show correlation between STS and SMI.Status Questionnaire pain, anxiety, and vitality scales also
contributing. In previous studies, serum CRP concentration has
been unfavourably related to physical performance, even within
low ranges [31]. In the present study, CRP also correlatedwith some
measures of performance (namely, IKES and TUG) suggesting that
systemic inﬂammation may play a role in patient functional limi-
tation, but these signiﬁcant associations were lost when correcting
for multiple comparisons.
The measures of CT SMI differed from the measures of MRI
quadriceps in their associations with performance. As thigh muscle
cross-sectional area and L3 muscle cross-sectional area both
correlate strongly with whole body muscularity [32], it might be
assumed that they should correlate directly with each other and
therefore equally with quadriceps strength and power. This
assumptionwas not found to be the case in our dataset. CT-SMI was
a predictor of STS and TUG. Both the STS and TUG tasks require the
use of a combination of lower limb and trunk motion initiated by
erector spinae and involving rectus abdominis in addition to
quadriceps and gluteal muscles [32]. Trunk muscles also make a
signiﬁcant contribution to balance and coordination. When weight
is shifted, the trunk responds to counteract the change in the centre
of gravity, maintaining postural control. Effective trunk muscle
function is essential for balance, transfers, gait, and the range of
activities in daily living [33]. Trunk muscle fatigue impairs balance
and functional task performance [34,35] and makes an equal or
greater contribution than limb muscle strength [32e35]. As a
result, in disease states with muscle wasting, CT SMI may be a
better surrogate measure of global functional impairment and
disability than MRI quadriceps.Fig. 3. Scatter chart to show correlation between MRI gross quadriceps CSA and power.
Fig. 4. Scatter chart to show correlation between MRI gross quadriceps CSA and
maximum strength.
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means processingwas observed to fail on several scans, either due to
low contrast across the scan as a whole or due to contrast gradients
on individual slices indicating that using MRI as a marker of
muscularity instead of CTcan bemore difﬁcult. IKESwas unavailable
in three patients. Patients with cancer cachexia can be very frail and
often struggle performing tasks asked of them. This is a very
important point to consider when deciding on the best functional
assessment for studies in order to ensure all are able to participate.
The ability to use imaging techniques as measures of patient func-
tion therefore are perhaps more appropriate in some settings. We
have previously shown that sexual dimorphism exists in skeletal
muscle mass, ﬁbre type and size and in response to neoplasm in this
patient group [24]. Sex speciﬁc analysis was not performed due to
the small numbers in this study but this is an important point to
consider in the design of future trials. There were outliers observed
(e.g. few peoplewith highmuscularity on CThad some of the longest
STS times) this maybe in part due to an unrecognised co-morbidity
preventing them from completing the test as required.
Conclusion
Both CT SMI andMRI quadriceps are potentially valid markers of
muscle function. However, these measures appear not to be inter-
changeable as they reﬂect different aspects of functional ability
with CT SMI being a better marker of global muscle function. The
mass of trunk muscles may play a different role in complex move-
ments compared with the mass of lower limb muscles. Consider-
ation of these differences is essential when selecting measures of
muscle mass or function for use in deﬁnitions of muscularity in
wasting conditions, or for use as outcome measures in studies of
wasting conditions. Further studies are required to ascertain the
best outcome measure.
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